FDA ‘Exception’ For Ipca’s Chloroquine/HCQ Amid Supply Plans From Others
Executive Summary
Import alert hit-Ipca gets a temporary reprieve from US FDA for supplies of hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials in the spotlight as potential treatments for COVID-19. But with many firms committing to supplies/donations, analysts appear to be tempering enthusiasm for large windfall gains for the Indian firm.
You may also be interested in...
India Bars Exports Of Hydroxychloroquine With Some Exceptions
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.
India COVID-19 Update: Antivirals, Eyes On HCQ-Azithromycin Data
Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.
Chloroquine Moves To Top of COVID-19 Clinical Trial List
Many hopes for an effective coronavirus treatment are being pinned on chloroquine, not least those of President Trump, and pharma companies are supplying the antimalarial to the US at no cost for use in clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: